1
Uyl - de Groot, Carin, Rooijen, Ellen, Punt, CJA, Pescott, CP
Veröffentlicht in: Uyl - de Groot , C , Rooijen , E , Punt , CJA & Pescott , CP 2018 , ' Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands ' , Health Economics Review , vol. 8 , no. 1 , pp. 13 . https://doi.org/10.1186/s13561-018-0197-3;
2018
Veröffentlicht in: Uyl - de Groot , C , Rooijen , E , Punt , CJA & Pescott , CP 2018 , ' Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands ' , Health Economics Review , vol. 8 , no. 1 , pp. 13 . https://doi.org/10.1186/s13561-018-0197-3;
2018
2
Xander, Nicolas S. H., Fiets, W. Edward, Uyl-de Groot, Carin A.
Veröffentlicht in: Frontiers in Oncology ; volume 13 ; ISSN 2234-943X;
2023
Veröffentlicht in: Frontiers in Oncology ; volume 13 ; ISSN 2234-943X;
2023
3
Luyendijk, Marianne, Blommestein, Hedwig, Uyl-de Groot, Carin, Siesling, Sabine, Jager, Agnes
Veröffentlicht in: Luyendijk , M , Blommestein , H , Uyl-de Groot , C , Siesling , S & Jager , A 2023 , ' Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands ' , JAMA network open , vol. 6 , no. 2 , e2256170 . https://doi.org/10.1001/jamanetworkopen.2022.56170;
2023
Veröffentlicht in: Luyendijk , M , Blommestein , H , Uyl-de Groot , C , Siesling , S & Jager , A 2023 , ' Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands ' , JAMA network open , vol. 6 , no. 2 , e2256170 . https://doi.org/10.1001/jamanetworkopen.2022.56170;
2023
4
Mohseninejad, Leyla, van Gils, Chantal, Uyl-de Groot, Carin A., Buskens, Erik, Feenstra, Talitha
Veröffentlicht in: Mohseninejad , L , van Gils , C , Uyl-de Groot , C A , Buskens , E & Feenstra , T 2015 , ' Evaluation of Patient Registries Supporting Reimbursement Decisions : The Case of Oxaliplatin for Treatment of Stage III Colon Cancer ' , Value in Health , vol. 18 , no. 1 , pp. 84-90 . https://doi.org/10.1016/j.jval.2014.10.008;
2015
Veröffentlicht in: Mohseninejad , L , van Gils , C , Uyl-de Groot , C A , Buskens , E & Feenstra , T 2015 , ' Evaluation of Patient Registries Supporting Reimbursement Decisions : The Case of Oxaliplatin for Treatment of Stage III Colon Cancer ' , Value in Health , vol. 18 , no. 1 , pp. 84-90 . https://doi.org/10.1016/j.jval.2014.10.008;
2015
5
6
Chen, Yi Hsuan, Blommestein, Hedwig M., Klazenga, Reinder, Uyl-de Groot, Carin, van Vulpen, Marco
Veröffentlicht in: Chen , Y H , Blommestein , H M , Klazenga , R , Uyl-de Groot , C & van Vulpen , M 2023 , ' Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands ' , Cancers , vol. 15 , no. 2 , 516 . https://doi.org/10.3390/cancers15020516;
2023
Veröffentlicht in: Chen , Y H , Blommestein , H M , Klazenga , R , Uyl-de Groot , C & van Vulpen , M 2023 , ' Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands ' , Cancers , vol. 15 , no. 2 , 516 . https://doi.org/10.3390/cancers15020516;
2023
7
de Groot, Saskia, Sleijfer, Stefan, Redekop, Ken, Oosterwijk, E, Haanen, JB, Kiemeney, LALM, Uyl - de Groot, Carin
Veröffentlicht in: de Groot , S , Sleijfer , S , Redekop , K , Oosterwijk , E , Haanen , JB , Kiemeney , LALM & Uyl - de Groot , C 2016 , ' Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry ' , BMC Cancer , vol. 16 , pp. 364 . https://doi.org/10.1186/s12885-016-2395-x;
2016
Veröffentlicht in: de Groot , S , Sleijfer , S , Redekop , K , Oosterwijk , E , Haanen , JB , Kiemeney , LALM & Uyl - de Groot , C 2016 , ' Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry ' , BMC Cancer , vol. 16 , pp. 364 . https://doi.org/10.1186/s12885-016-2395-x;
2016
8
de Kleijn, Ria, Uyl-de Groot, Carin, Hagen, Chris, Diepenbroek, Adry, Pasker-de Jong, Pieternel, ter Wee, Piet
Veröffentlicht in: de Kleijn , R , Uyl-de Groot , C , Hagen , C , Diepenbroek , A , Pasker-de Jong , P & ter Wee , P 2017 , ' Differences in care burden of patients undergoing dialysis in different centres in the netherlands ' , Journal of Renal Care , vol. 43 , no. 2 , pp. 98-107 . https://doi.org/10.1111/jorc.12193;
2017
Veröffentlicht in: de Kleijn , R , Uyl-de Groot , C , Hagen , C , Diepenbroek , A , Pasker-de Jong , P & ter Wee , P 2017 , ' Differences in care burden of patients undergoing dialysis in different centres in the netherlands ' , Journal of Renal Care , vol. 43 , no. 2 , pp. 98-107 . https://doi.org/10.1111/jorc.12193;
2017
9
Franken, Margreet, Kanters, Tim, Coenen, JL, De Jong, P, Koene, HR, Lugtenburg, Elly, Jager, Agnes, Uyl - de Groot, Carin
Veröffentlicht in: Franken , M , Kanters , T , Coenen , JL , De Jong , P , Koene , HR , Lugtenburg , E , Jager , A & Uyl - de Groot , C 2018 , ' Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands ' , Anti-Cancer Drugs , vol. 29 , no. 8 , pp. 791-801 . https://doi.org/10.1097/CAD.0000000000000648;
2018
Veröffentlicht in: Franken , M , Kanters , T , Coenen , JL , De Jong , P , Koene , HR , Lugtenburg , E , Jager , A & Uyl - de Groot , C 2018 , ' Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands ' , Anti-Cancer Drugs , vol. 29 , no. 8 , pp. 791-801 . https://doi.org/10.1097/CAD.0000000000000648;
2018
10